Physiological and Immunological Disturbance in Rheumatoid Arthritis Patients
Article Sidebar
Main Article Content
Abstract
Rheumatoid arthritis (RA) is a systematic autoimmune disorder with chronic inflammation changes of unknown etiology. Various synovial inflammatory and proliferative alterations may contribute to the cartilaginous tissues and invasive bony tissues, leading to destructive joints and malformed bones. This disease is mostly due to infective microorganisms or genetic susceptibility causing immune system disturbances through triggering both T-cells and B-cells. Furthermore, different immune cells may secret cytokines, which are responsible for some RA pathogenesis activity. From ninety individuals, serum sample was collected; thirty of them were normal and sixty cases were patients with RA attended a privet medical clinic at Tikrit city from May 2019 to November 2019. Age, in both patients and control groups, ranged between (18-50) years, they had assay of Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Tumor necrosis factor (TNF)-α, Leptin, Adiponectin, and C-reactive protein. The present study shows that (IL-1, Leptin, and CRP) levels were higher in Rheumatoid Arthritis patients than control, while (IL-6, IL-10, TNFα, and ADP) levels were lower; therefore, cytokines can play an essential role in RA pathogenesis. The current study may bring attention to adiponectin and leptin for their roles in the pathogenesis of RA. Special consideration was devoted to those proteins, which act on cells associated with RA, also for possible usage of these protein levels as potential biomarkers for the disease activity and therapeutic response.
Received 27/6/2020, Accepted 30/12/2020, Published Online First 11/1/2021
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Oton T, Carmona L. The epidemiology of established Rheumatoid Arthritis. Best Pract Res Clin Rheumatol. 2019;33(5):101477.
Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, et al. Risk for lower intestinal perforations in patients with Rheumatoid Arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheumatol Dis.2017;76:504-10.
Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of Rheumatoid Arthritis. Ann Rheumatol Dis. 2017;76:1101-36.
Klaresgog L.Understanding and prevention of the evolution towards autoimmune Rheumatoid Arthritis: the new challenge. Clin Ther. 2019;41:1232-4.
Weyand CM, Goronzy JJ. Immunometabolism in early and late stages of Rheumatoid Arthritis. Nat Rev Rheumatol. 2017;13:291-301.
Wu C, Yang H, Lai J. Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis: Biological Effects and Mechanisms of Immunopathogenesis. Int J Mol Sci. 2020;21:4015.
Gallenga CE, Pandolfi F, Caraffa Al, Kritas SK, Ronconi G, Toniato E, et al. Interleukin-1 family cytokines and mast cells: activation and inhibition. J Biol Regul Homeost Agents. 2019;33:1-6.
Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, et al. Tocilizumab improves the proatherothrombotic profile of Rheumatoid Arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res. 2017;183:87-103.
Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for Rheumatoid Arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34:788-802.
Mercado MV, Martinez-Garcia EA. Leptin as an open secret in the physiopathology of Rheumatic disease. Clin Rheumatol. 2020;39:301-3.
Mosanya CH, Isaacs JD. Tolerating cellular therapies: what is their promise for autoimmune disease? Ann Rheumatol Dis. 2019;78:297-310.
Otero M, Lago R, Lago F, Reino JJ, Gualillo O. Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res Ther. 2005;7:581-91.
Wadström H, Frisell T, Askling J. Malignant neoplasms in patients with Rheumatoid Arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. JAMA Intern Med. 2017;177:1605.
Ruscitti P, Benedetto P D, Berardicurti O, Giacomelli R. Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. J Immun Res. 2018;1:1-10.
Sunlong Biotech Co. Human Elisa kit. Available from: https://www.sunlongbiotech.com/gory.php?id=66. [Accessed 2 December 2020].
Petra CV, Vonica CL, Rahaian R, Rednic S, Vesa SC, Zdrenghea M, et al. Circulating leptin and resistin levels in a Romanian Rheumatoid Arthritis population. Roman J Rheumatol. 2020;29(2):79-83.
Costello R, David T, Jani M. Impact of adverse events associated with medications in the treatment and prevention of Rheumatoid Arthritis. Clin Ther. 2019;41:1376-96.
Hayashi H, Satoi K, Sato-Mito N, Kaburagi T, Yoshino H, Higaki M, et al. Nutritional status in relation to adipokines and oxidative stress is associated with disease activity in patients with Rheumatoid Arthritis. Nutrition. 2012;28:1109-14.
Hazlewood GS, Bombardier C, Tomlinson G, Thorne C, Bykerk VP, Thompson A, et al. Treatment preferences of patients with early Rheumatoid Arthritis: a discrete-choice experiment. Rheumatol (United Kingdom). 2016;55:1959-68.
Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of Rheumatoid Arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018;37:2611-20.
Sandell LJ. Obesity and osteoarthritis: is leptin the link? Arthritis Rheumatol. 2009; 60: 2858-60.
Targonska-Stepniak B, Majdan M, Dryglewska M. Leptin serum levels in Rheumatoid Arthritis patients: relation to disease duration and activity. Rheumatol Int. 2008;28:585-91.
Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheumatol Dis. 2012;71(5):753-60.
Ali S, Hussein SZ, Hussain WN. Study of the Correlation between Serum C-reactive Protein and Bone Biochemical Markers in Type 2 Diabetic Individuals. Tikrit J Pure Sci. 2014;19(5):58-64.
Wang K, Chen L, Liu L, Cui Y, Zhang X, Jiang J. The effects of atorvastatin on IL-6, CRP, blood lipid and myocardial protection of interventional therapy in patients with acute myocardial infarction. Minerva Med. 2019;110:101-6.
Pozzi D, Menna M, Canzi A, Desiato G, Mantovani C, Matteoli M. The communication between the immune and nervous systems: the role of IL-1β in synaptopathies. Front Mol Neurosci. 2018;11:111.
Caraffa Al, Conti C, D Ovidio C, Gallenga CE, Tettamanti L, Mastrangelo F, et al. New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory mediators. J Biol Regul Homeost Agents. 2018;32:1345-7.
Yang M, Haase C, Viljanen J, Xu B, Ge C, Kihlberg J, et al. Cutting edge: processing of oxidized peptides in macrophages regulates T cell activation and development of autoimmune arthritis. J Immunol. 2017;199:3937-42.
Conti P, Caraffa A, Mastrangelo F, Tettamanti L, Ronconi G, Frydas I, et al. Critical role of inflammatory mast cell in fibrosis: potential therapeutic effect of IL-37. Cell Prolif. 2018;51:12475.
Greenblatt HK, Kim HA, Bettner LF, Deane KD. Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention. Cur Opin Rheumatol. 2020;32(3):1-6.
Turner JJ, Smolinska MJ, Sacre SM, Foxwell BM. Induction of TLR tolerance in human macrophages by adiponectin: does LPS play a role? Scand J Immunol. 2009;69(4):329-36.
Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with Rheumatoid Arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17:215-25.
Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nature Med. 2011;17(1):55-63.
Chan D, Goruk S, Becker AB, Subbarao P, Mandhane PJ, Turvey SE, et al. Adiponectin, leptin and insulin in breast milk: associations with maternal characteristics and infant body composition in the first year of life. Int J Obes (Lond). 2018;42:36-43.
Pontes C, Marsal JR, Elorza JM, Aragon M, Prieto-Alhambra D, Morros R. Analgesic Use and Risk for Acute Coronary Events in Patients with Osteoarthritis: A Population-based, Nested Case-control Study. Clin Ther. 2018;40(2):270-83.
Srivastava SB, Fluegel N, Mansukhani RP. Pharmacologic Management of Rheumatoid Arthritis. Orthop Nurs. 2019;38(6):390-5.
Bankó Z, Pozsgay J, Gáti T, Rojkovich B, Ujfalussy I, Sármay G. Regulatory B cells in Rheumatoid Arthritis: alterations in patients receiving anti-TNF therapy. Clin Immunol. 2017;184:63-9.
Li N, Betts KA, Messali AJ, Skup M, Garg V. Real-world Effectiveness of Biologic Disease-modifying AntiRheumatolatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Clin Ther. 2017;39(8):1618-27.
Mendes MT, Alponti RF, Alves PL, Trevizan IL, Markus RP, Fernandes PA, et al. Inhibitors of Tumor Necrosis Factor Synthesis as a New Approach for the Treatment of Rheumatoid Arthritis. J Arthritis. 2020;9(4):001-7.
Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheumatol Dis. 2017;76:497-503.
Gruol DL. Impact of increased astrocyte expression of IL-6, CCL2 or CXCL10 in transgenic mice on synaptic function. Brain Sci. 2016;6:19.